Personal Genome Diagnostics

67 articles about Personal Genome Diagnostics

• Labcorp Completes Acquisition of Personal Genome Diagnostics

  2/21/2022

  Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc.

• PGDx Announces an Updated Medicare Reimbursement Rate for the elio™ tissue complete Test

  1/25/2022

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced an update to the Proprietary Laboratory Analyses (PLA) code for its comprehensive genomic profiling test, PGDx elio™ tissue complete.

• Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services

  12/23/2021

  Labcorp today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. ( PGDx ), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

• Personal Genome Diagnostics and Cleveland Clinic Collaborate to Expand Utility of Liquid Biopsy Applications in Oncology Clinical Research

  9/21/2021

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a collaboration with the Center for Immunotherapy and Precision Immuno-Oncology (CITI) and the Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.

• New Paper Highlights Capability of Personal Genome Diagnostics’ elio™ plasma resolve Assay to Detect Microsatellite Instability

  8/11/2021

  Personal Genome Diagnostics Inc. (PGDx) today reported the publication of a research paper in The Oncologist, titled “Validation of a ctDNA-based next-generation sequencing assay in a cohort of solid tumor patients: a proposed solution for decentralized plasma testing,” which assessed the performance of the company’s elio™ plasma resolve assay.

• Personal Genome Diagnostics Appoints Maggie Rougier-Chapman as Senior Vice President, Head of Marketing and Commercial Strategy

  8/4/2021

  Personal Genome Diagnostics Inc. today announced the appointment of Maggie Rougier-Chapman as Senior Vice President, Head of Marketing and Commercial Strategy.

• Personal Genome Diagnostics Appoints Jamie Platt, Ph.D., as Chief Operations Officer

  8/3/2021

  Personal Genome Diagnostics Inc. today announced the appointment of Jamie Platt, Ph.D., as Chief Operations Officer.

• Personal Genome Diagnostics Appoints Mark Sausen as Vice President, Technology Innovation

  7/13/2021

  Personal Genome Diagnostics Inc. today announced the appointment of Mark Sausen, Ph.D., as Vice President, Technology Innovation.

• Personal Genome Diagnostics and Massachusetts General Hospital Enter Strategic Collaboration to Advance Development of Precision Diagnostics

  6/24/2021

  Personal Genome Diagnostics Inc. (PGDx) today announced a strategic collaboration with Massachusetts General Hospital (MGH).

• Personal Genome Diagnostics Appoints Brent Dial as Chief Financial Officer

  6/9/2021

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Brent Dial, MBA, as Chief Financial Officer.

• Personal Genome Diagnostics and Fox Chase Cancer Center Announce Partnership to Broaden Liquid Biopsy Applications in Oncology Clinical Research

  2/23/2021

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a strategic collaboration with Fox Chase Cancer Center in Philadelphia for the PGDx elio™ plasma resolve liquid biopsy panel.

• Personal Genome Diagnostics Announces Close of $103 Million Series C Financing

  2/10/2021

  Proceeds to Support Expansion of Commercial Infrastructure Driving Decentralization of Comprehensive Genomic Profiling for Cancer PGDx’s elio™ Platform and Bioinformatics Solution Enable Hospitals and Labs to Deliver World-Class, Actionable Genomic Information to Physicians and Their Patients

• Personal Genome Diagnostics and QIAGEN Collaborate to Offer Integrated Genomic Testing and Interpretation Support

  1/13/2021

  Partnership to Accelerate Adoption of Next-Generation Sequencing (NGS) in Clinical Decision-Making Comprehensive Pan-Cancer Tumor Profiling Assays can be Combined with Clinical Informatics Platform with Potential to Reduce Time to Results and Complexity of Clinical Genomic Analysis

• Personal Genome Diagnostics Announces Medicare Coverage of PGDx elio™ tissue complete Assay for Patients with Advanced Cancer

  9/9/2020

  Reimbursement Now Available for Comprehensive Test that can be Performed in Labs Across the Country, Expanding Local Access to Personalized Cancer Care BALTIMORE--( BUSINESS WIRE )-- Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today that the CMS Molecular Diagnostics Program (MolDX) has issued a local coverage determination (LCD) for the FDA-cleared PGDx elio™ tissue complete assay. The MolDX coverage determination

• Personal Genome Diagnostics Appoints Megan Bailey as Chief Executive Officer

  4/21/2020

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, appointed Megan Bailey as Chief Executive Officer (CEO), promoted from Chief Commercial Officer (CCO).

• Personal Genome Diagnostics Appoints Megan Bailey as Chief Commercial Officer

  1/28/2020

  Industry veteran to drive global commercialization of cancer genomics product line

• Personal Genome Diagnostics and Eisai Co., Ltd. Collaborate to Develop Comprehensive Liquid Biopsy Biomarker Discovery Solution

  1/15/2020

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, is partnering with Eisai Co., Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology, to be used by Eisai researchers at their Tsukuba Research Laboratory.

• Personal Genome Diagnostics and Mayo Clinic Enter Strategic Collaboration to Enhance Patient Care in Oncology

  1/8/2020

  Technology optimization and clinical utility studies to enhance liquid biopsy and tissue-based genomic applications for cancer patients

• Personal Genome Diagnostics Receives Investigational Device Exemption Approval from the FDA to Support Merck’s Precision Oncology Trial

  12/4/2019

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for the use of the company’s elio™ tissue complete assay in a Merck trial of pembrolizumab-based combination therapy.

• Personal Genome Diagnostics CE Marks PGDx elio™ Tissue Complete Assay

  9/25/2019

  Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to the PGDx elio™ tissue complete assay.